Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free TRVN Stock Alerts

Trevena (TRVN) Competitors

Trevena logo
$0.0010 0.00 (0.00%)
As of 08/7/2026
Compare

TRVN vs. CLVR, SCPS, SYRS, NAVB, and WINT

Should you buy Trevena stock or one of its competitors? Trevena's main competitors and comparable companies include Clever Leaves (CLVR), Scopus BioPharma (SCPS), Syros Pharmaceuticals (SYRS), Navidea Biopharmaceuticals (NAVB), and Windtree Therapeutics (WINT). Companies are selected based on similarities in market, industry, and size.

How does Trevena compare to Clever Leaves?

Trevena (NASDAQ:TRVN) and Clever Leaves (NASDAQ:CLVR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Clever Leaves N/A N/A N/A

Clever Leaves has higher revenue and earnings than Trevena. Clever Leaves is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.00-$40.29M-$47.04N/A
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A

Trevena has a beta of -0.44, indicating that its share price is 144% less volatile than the broader market. Comparatively, Clever Leaves has a beta of 3816.13, indicating that its share price is 381,513% more volatile than the broader market.

In the previous week, Trevena's average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company Overall Sentiment
Trevena Neutral
Clever Leaves Neutral

13.6% of Trevena shares are owned by institutional investors. Comparatively, 6.9% of Clever Leaves shares are owned by institutional investors. 2.7% of Trevena shares are owned by company insiders. Comparatively, 8.2% of Clever Leaves shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Clever Leaves beats Trevena on 6 of the 9 factors compared between the two stocks.

How does Trevena compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and Trevena (NASDAQ:TRVN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Trevena Neutral

Scopus BioPharma has a beta of -0.19, indicating that its share price is 119% less volatile than the broader market. Comparatively, Trevena has a beta of -0.44, indicating that its share price is 144% less volatile than the broader market.

Scopus BioPharma has higher earnings, but lower revenue than Trevena.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Trevena$443K0.00-$40.29M-$47.04N/A

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Trevena N/A N/A -119.55%

13.6% of Trevena shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by company insiders. Comparatively, 2.7% of Trevena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Scopus BioPharma beats Trevena on 4 of the 6 factors compared between the two stocks.

How does Trevena compare to Syros Pharmaceuticals?

Syros Pharmaceuticals (NASDAQ:SYRS) and Trevena (NASDAQ:TRVN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

Syros Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market. Comparatively, Trevena has a beta of -0.44, meaning that its stock price is 144% less volatile than the broader market.

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company Overall Sentiment
Syros Pharmaceuticals Neutral
Trevena Neutral

Trevena has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syros Pharmaceuticals$386K0.01-$164.57M-$3.03N/A
Trevena$443K0.00-$40.29M-$47.04N/A

Trevena's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Syros PharmaceuticalsN/A -3,369.56% -97.04%
Trevena N/A N/A -119.55%

91.5% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by insiders. Comparatively, 2.7% of Trevena shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Syros Pharmaceuticals beats Trevena on 6 of the 10 factors compared between the two stocks.

How does Trevena compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Trevena (NASDAQ:TRVN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Navidea Biopharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market. Comparatively, Trevena has a beta of -0.44, meaning that its stock price is 144% less volatile than the broader market.

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Trevena Neutral

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Comparatively, 2.7% of Trevena shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Trevena. Trevena is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Trevena$443K0.00-$40.29M-$47.04N/A

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Trevena N/A N/A -119.55%

Summary

Navidea Biopharmaceuticals beats Trevena on 5 of the 8 factors compared between the two stocks.

How does Trevena compare to Windtree Therapeutics?

Trevena (NASDAQ:TRVN) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

In the previous week, Trevena's average media sentiment score of 0.00 equaled Windtree Therapeutics'average media sentiment score.

Company Overall Sentiment
Trevena Neutral
Windtree Therapeutics Neutral

13.6% of Trevena shares are owned by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are owned by institutional investors. 2.7% of Trevena shares are owned by company insiders. Comparatively, 0.2% of Windtree Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Trevena has a beta of -0.44, suggesting that its share price is 144% less volatile than the broader market. Comparatively, Windtree Therapeutics has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market.

Trevena's return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Windtree Therapeutics N/A -207.34%-50.19%

Windtree Therapeutics has lower revenue, but higher earnings than Trevena. Windtree Therapeutics is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.00-$40.29M-$47.04N/A
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A

Summary

Windtree Therapeutics beats Trevena on 5 of the 9 factors compared between the two stocks.

Get Trevena News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TRVN vs. The Competition

Export
MetricTrevenaPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1K$11.81B$7.01B$12.98B
Dividend YieldN/A2.69%2.58%10.07%
P/E Ratio0.00788.51269.1824.72
Price / Sales0.00747.68589.7298.19
Price / CashN/A15.1228.8937.42
Price / Book0.0010.2811.346.42
Net Income-$40.29M$2.77B$3.45B$347.03M
7 Day PerformanceN/A0.86%1.94%0.71%
1 Month PerformanceN/A-1.58%-0.56%-0.87%
1 Year PerformanceN/A183.20%75.50%21.94%

Trevena Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TRVN
Trevena
N/A$0.00
flat		N/A-99.6%$1K$443KN/A40
CLVR
Clever Leaves
N/A$0.01
flat		N/A+3,250.0%$18K$17.42MN/A560
SCPS
Scopus BioPharma
N/A$0.00
-20.0%		N/AN/A$17KN/AN/A9
SYRS
Syros Pharmaceuticals
N/A$0.00
+300.0%		N/A-90.9%$11K$386KN/A120
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TRVN) was last updated on 8/11/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel